Sangamo Therapeutics (SGMO) Misses Q1 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. MSFT
3. PLTR
4. SPY
5. CSCO
6. KTOS
7. JPM
8. DT
9. AON
10. TMUS

Go back to Sangamo Therapeutics (SGMO) Misses Q1 EPS by 8c

Sangamo Therapeutics Reports Business Highlights and First Quarter 2020 Financial Results

May 11, 2020 4:01 PM EDT

Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time

BRISBANE, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported first quarter 2020 financial results and recent business highlights.

Im proud of how the Sangamo team has worked together through the unusual circumstances presented by the COVID-19 pandemic, said Sandy Macrae, CEO of Sangamo. While adhering to governmental workplace guidelines, we have sought to minimize disruptions to the progress of our research in the labs, our clinical trials, and our business development... More